Please assess the completion status of the following clinical trial:

Trial Title: Prospective Evaluation of the Efficacy of Budesonide/Formoterol in Bronchiolitis Obliterans in AHSCT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥16 years.~* Previous normal PFTs available.~* Absence of extrathoracic GVH disease justifying initiation or intensification of systemic immunosuppressive therapy.~* Respiratory signs present for less than 6 months.~* AHSCT recipients who have developed moderate to severe bronchiolitis obliterans, defined by reduction of FEV1/VC below the 5th percentile of predicted normal or \< 80% of predicted, with FEV1 \< 80% of predicted and ≥ 40% of predicted, not reversible after inhalation of short-acting beta-2 agonist. AHSCT recipients with FEV1 \< 80% of predicted and ≥ 40% of predicted, not reversible after inhalation of short-acting beta-2 agonist and TLC ≥ 80% of predicted.~* Respiratory symptoms related to obstructive lung disease present for at least 6 months.~* Negative respiratory microbiology work-up.~* Informed consent signed by the patient or both parents of a minor.~Exclusion Criteria:~* Extrathoracic graft versus host reaction justifying initiation or intensification of systemic immunosuppressive therapy.~* Use of inhaled bronchodilator and/or corticosteroid therapy at the time of inclusion.~* Known intolerance to inhaled bronchodilators and/or corticosteroids and/or lactose.~* Personal or donor history of asthma.~* Active smoking~* FEV1 \< 40% of predicted normal or ≥ 80% of predicted normal or PO2 \< 50 mmHg.~* Documented respiratory tract infection.~* Pregnancy.~* Absence of effective contraception during the trial.~* Not covered by French national health insurance.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Patients with OAD will receive Symbicort® at the dose of two puffs morning and evening, each delivering 400/12 µg of budesonide/formoterol. Symbicort® will be administered by inhalation using the Turbuhaler (TH) system
- 2 (Type: PLACEBO_COMPARATOR): Patients with OAD will receive lactose as a placebo, administered by inhalation using the Turbuhaler (TH) system

Based on this trial design, predict the completion outcome and termination type (if applicable).